They help people live a long and healthy life. One such Fortune 500 pharma company wanted to analyze the biomarker data and unmined clinical trial. Modak Analytics, along with a consultant team, undertook this transformation. There were many challenges:
Modak developed a system for integrating new studies that have already been standardized to SDTM (Study Data Tabulation Model) format. This helps to scale the larger number of legacy studies that could not be addressed and where ETL and statistical programming could not keep up. Modak combined machine learning and expert analytical tools to map legacy clinical trials to the master schema by:
Modak’s Novel approach of preparing data for downstream analytics enables scientists to access more data to make better, faster, and more accurate decisions. Moreover, it enables biopharmaceutical organizations to finally see a return on their enormous data investment.